blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1668354

EP1668354 - METHOD OF DIAGNOSING BREAST CANCER [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  17.07.2009
Database last updated on 12.07.2024
Most recent event   Tooltip13.11.2009Change - applicantpublished on 16.12.2009  [2009/51]
Applicant(s)For all designated states
Oncotherapy Science, Inc.
2-1, Sakado 3-chome Takatsu-ku Kawasaki-shi
Kanagawa 213-0012 / JP
[2009/51]
Former [2006/33]For all designated states
Oncotherapy Science, Inc.
2-1, Sakado 3-chome, Takatsu-ku
Kawasaki-shi, Kanagawa 213-0012 / JP
Former [2006/24]For all designated states
Oncotherapy Science, Inc.
2-1, Sakado 3-chome, Takatsu-ku
Kawasaki-shi, Kanagawa 213-0012 / JP
For all designated states
The University of Tokyo
3-1, Hongo 7-chome, Bunkyo-ku
Tokyo 1138654 / JP
Inventor(s)01 / NAKAMURA, Yusuke
17-33, Azamino 1-chome, Aoba-ku
Yokohama-shi, Kanagawa 2250011 / JP
02 / KATAGIRI, Toyomasa university of Tokio
3-1, Hongo 7-chome, Bunkyu-ku
Tokyo, 113-8654 / JP
03 / NAKATSURU, Shuichi
6-2, Shimoochiai 2-chome, Chuo-ku
Saitama-shi, Saitama 3380002 / JP
 [2006/40]
Former [2006/24]01 / NAKAMURA, Yusuke
17-33, Azamino 1-chome, Aoba-ku
Yokohama-shi, Kanagawa 2250011 / JP
02 / KATAGIRI, Toyomasa
2-10-11-305, Higashigotanda, Shinagawa-ku
Tokyo, 1410022 / JP
03 / NAKATSURU, Shuichi
6-2, Shimoochiai 2-chome, Chuo-ku
Saitama-shi, Saitama 3380002 / JP
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[N/P]
Former [2008/35]Vossius & Partner
Siebertstrasse 3
81675 München / DE
Former [2006/24]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Application number, filing date04771702.010.08.2004
[2006/24]
WO2004JP11741
Priority number, dateUS20030505571P24.09.2003         Original published format: US 505571 P
[2006/24]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2005029067
Date:31.03.2005
Language:EN
[2005/13]
Type: A2 Application without search report 
No.:EP1668354
Date:14.06.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 31.03.2005 takes the place of the publication of the European patent application.
[2006/24]
Search report(s)International search report - published on:EP18.08.2005
ClassificationIPC:G01N33/48, C12Q1/68
[2006/24]
CPC:
C12Q1/6886 (EP,US); A61P35/00 (EP); A61P35/04 (EP);
C07K14/4702 (EP,US); G01N33/57415 (EP,US); C12Q2600/112 (EP,US);
C12Q2600/118 (EP,US); C12Q2600/136 (EP,US); C12Q2600/156 (EP,US);
C12Q2600/158 (EP,US); G01N2500/04 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/24]
Extension statesALNot yet paid
HRNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:METHODE ZUR DIAGNOSE VON BRUSTKREBS[2006/24]
English:METHOD OF DIAGNOSING BREAST CANCER[2006/24]
French:METHODE DE DIAGNOSTIC DU CANCER DU SEIN[2006/24]
Entry into regional phase21.04.2006National basic fee paid 
21.04.2006Designation fee(s) paid 
21.04.2006Examination fee paid 
Examination procedure21.04.2006Amendment by applicant (claims and/or description)
21.04.2006Examination requested  [2006/24]
05.06.2007Despatch of a communication from the examining division (Time limit: M04)
15.10.2007Reply to a communication from the examining division
21.10.2008Despatch of a communication from the examining division (Time limit: M04)
03.03.2009Application deemed to be withdrawn, date of legal effect  [2009/34]
03.04.2009Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2009/34]
Fees paidRenewal fee
21.04.2006Renewal fee patent year 03
31.08.2007Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.08.200805   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO0204514  (CORIXA CORP [US], et al) [Y] 1-39,41-43 * See entire document, esp. Example 13 and SEQ ID NO: 1904. *;
 [X]US6365358  (HILLMAN JENNIFER L [US], et al) [X] 1-39,41-43 * See entire document, especially: SEQ ID NO: 1; column 25, line 62 - column 26, line 1; claims. *;
 [Y]  - "Sequence 1 from patent US 6365358.", USPTO Proteins, (20020620), Database accession no. AAM56211, URL: EBI, XP002307509 [Y] 1-39,41-43 * See sequence listing *
 [Y]  - "Sequence 1904 from Patent WO0204514.", EPO Proteins, (20020215), Database accession no. AX369194, URL: EBI, XP002307510 [Y] 1-39,41-43 * See Sequence listing *
 [Y]  - LIPKOWITZ S, "The role of the ubiquitination-proteasome pathway in breast cancer. Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer", BREAST CANCER RESEARCH 2003 UNITED KINGDOM, (2003), vol. 5, no. 1, ISSN 1465-5411, pages 8 - 15, XP002307507 [Y] 12-21 * Introduction, page 12, LH column, 3rd paragraph until end page 13; conclusion. *
 [Y]  - ORLOWSKI ROBERT Z ET AL, "The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.", BREAST CANCER RESEARCH : BCR. 2003, (2003), vol. 5, no. 1, ISSN 1465-542X, pages 1 - 7, XP002307508 [Y] 12-21 * Abstract, Table 1, "Future directions" on P. 5- 6; Conclusions *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.